Actrapid FlexPen 100 IU/ml solution for injection in apre-filled pen

ATC Code
Actrapid FlexPen 100 IU/ml solution for injection in apre-filled pen

Novo Nordisk A/S

Insulin (human)
Narcotic Psychotropic
No No
Pharmacological group Insulins and analogues


All to know


Novo Nordisk A/S

What is it?

Actrapid is a solution for injection. It is available in a vial, a cartridge (PenFill) or in a prefilled pen (NovoLet, FlexPen or InnoLet). Actrapid contains the active substance insulin human (rDNA).

What is it used for?

Actrapid is used in patients who have diabetes.
The medicine can only be obtained with a prescription.


How is it used?

Actrapid is administered subcutaneously (under the skin) by injection, usually into the abdominal wall (tummy). The thigh, the deltoid region (shoulder) or the gluteal region (buttocks) may also be used. The patient's blood glucose (sugar) should be tested regularly to find the lowest effective dose. The usual dose is between 0.3 and 1.0 international units (IU) per kilogram body weight per day. Actrapid is given 30 minutes before a meal. Actrapid is a fast-acting insulin and may be used with long-acting insulins. Actrapid may also be given intravenously (into a vein) but only by a doctor or a nurse.

How does it work?

Diabetes is a disease in which the body does not produce enough insulin to control the blood glucose. Actrapid is a replacement insulin that is identical to the insulin made by the pancreas. The active substance in Actrapid, insulin human (rDNA), is produced by a method known as ?recombinant technology?: the insulin is made by a yeast that has received a gene (DNA), which makes it able to produce insulin. The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the blood glucose, the symptoms and complications of diabetes are reduced.

How has it been studied?

Actrapid has been studied in patients with type 1 diabetes,when the pancreas cannot produce insulin (two studies involving 1,954 patients), and type 2 diabetes, when the body is unable to use insulin effectively (one study involving 182 patients). The studies compared Actrapid to a human insulin analogue (insulin aspart) over six months by measuring the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.

What benefits has it shown during the studies?

HbA1c levels remained fairly steady over the six months of treatment with Actrapid.

What is the risk associated?

As with all insulins, Actrapid may cause hypoglycaemia (low blood glucose). For the full description of all side effects reported with Actrapid, see the Package Leaflet.
Actrapid should not be used in people who may be hypersensitive to insulin human (rDNA) or any of the other ingredients. Actrapid doses might also need to be adjusted when given with a number of other medicines which may have an effect on blood glucose. The full list is available in the Package Leaflet.

Why has it been approved?

The Committee for Medicinal products for Human Use (CHMP) decided that Actrapid?s benefits are greater than its risks for the treatment of diabetes mellitus. The Committee recommended that Actrapid be given marketing authorisation.



Your personal medicine assistent


Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.

This website is certified by Health On the Net Foundation. Click to verify.